phase 1_completion
saveUniversity of Texas MD Anderson Cancer Center — bevacizumab (Phase I Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Advanced Malignancy, Metastatic Cancer, Solid Tumor
Data sources
globaldata
Found something off?
drug timeline · 4
- phase 1 2 completionIRCCS Foundation National Cancer Institute — bevacizumab (Phase I/II Trial Completion)Apr 30, 2026 · 163d ago
- phase 1 2 initiationBeijing Bethune Charitable Foundation — bevacizumab (Phase I/II Trial Initiation)Apr 30, 2026 · 163d ago
- phase 2 3 completionFaculty of Medicine Siriraj Hospital Mahidol University — bevacizumab (Phase II/III Trial Completion)Apr 28, 2026 · 165d ago
- phase 2 completionUniversity Health Network — bevacizumab (Phase II Trial Completion)Apr 24, 2026 · 169d ago
related news · 8
- oncliveDr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
- oncliveFDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
- oncliveDr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
- oncliveFive Under 5: Top Oncology Videos for the Week of 5/3
- oncliveUT MD Anderson Shares Latest Research Breakthroughs
- oncliveDr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
- oncliveTrack the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
- oncliveDr Pant on the Mechanism of Action of Daraxonrasib in PDAC
🐶 often sniffed alongside
top 8- tagOncology11 co-mentions · 4 sources
- tagRecall6 co-mentions · 4 sources
- drugGP-25 co-mentions · 3 sources
- drugbevacizumab biosimilar5 co-mentions · 3 sources
- tagColorectal Cancer3 co-mentions · 2 sources
- companyIRCCS Foundation National Cancer Institute1 co-mentions · 1 sources
- companyBeijing Bethune Charitable Foundation1 co-mentions · 1 sources
- companyUniversity of Texas MD Anderson Cancer Center1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that